The Role of Positron Emission Tomography/Computed Tomography in the Management of Differentiated Thyroid Cancer: Current Applications and Future Perspectives

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Nov 27

PMID 39598062

Authors

Emmanouil Panagiotidis

Jules Tianyu Zhang-Yin

Affiliations

Soon will be listed here.

Abstract

Differentiated thyroid cancer (DTC), comprising papillary and follicular thyroid carcinoma, is the most common thyroid malignancy and typically has a favourable prognosis when detected early. Positron emission tomography/computed tomography (PET/CT) has emerged as a valuable imaging modality, integrating metabolic and anatomical data. Although PET/CT is not usually part of the initial diagnostic process due to DTC's indolent nature and low metabolic activity, it plays an essential role in selected clinical scenarios. This includes identifying recurrence in patients with elevated thyroglobulin (Tg) levels and negative radioactive iodine (RAI) scans, evaluating metastatic disease, and guiding treatment in advanced cases. As the use of PET/CT evolves in oncology, this review explores its application in regard to staging, detection of recurrence, and follow-up in terms of managing DTC while also evaluating potential challenges that may occur in the future. The review also considers emerging radiotracers and the theragnostic potential of PET/CT.

References

Lebbink C, Links T, Czarniecka A, Dias R, Elisei R, Izatt L . 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022; 11(6). PMC: 9716393. DOI: 10.1530/ETJ-22-0146. View

Pattison D, Bozin M, Gorelik A, Hofman M, Hicks R, Skandarajah A . F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. J Nucl Med. 2017; 59(5):749-755. DOI: 10.2967/jnumed.117.198085. View

Schlumberger M, TUBIANA M, De Vathaire F, Hill C, Gardet P, Travagli J . Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986; 63(4):960-7. DOI: 10.1210/jcem-63-4-960. View

Giovanella L, Trimboli P, Verburg F, Treglia G, Piccardo A, Foppiani L . Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2013; 40(6):874-80. DOI: 10.1007/s00259-013-2370-6. View

Ju S, Lee S, Yi S, Choi N, Kim K, Kim S . Transcriptomic characteristics according to tumor size and SUV in papillary thyroid cancer patients. Sci Rep. 2024; 14(1):11005. PMC: 11094162. DOI: 10.1038/s41598-024-61839-0. View

Mazzaferri E, Jhiang S . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97(5):418-28. DOI: 10.1016/0002-9343(94)90321-2. View

Albano D, Tulchinsky M, Dondi F, Mazzoletti A, Lombardi D, Bertagna F . Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020; 48(2):461-468. PMC: 7835169. DOI: 10.1007/s00259-020-04992-8. View

Ventura D, Dittmann M, Buther F, Schafers M, Rahbar K, Hescheler D . Diagnostic Performance of [F]TFB PET/CT Compared with Therapeutic Activity [I]Iodine SPECT/CT and [F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma. J Nucl Med. 2024; 65(2):192-198. PMC: 10858375. DOI: 10.2967/jnumed.123.266513. View

Miller M, Chen Q, Elashoff D, Abemayor E, St John M . Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2010; 33(4):562-5. DOI: 10.1002/hed.21492. View

10.

Lubberink M, Abdul Fatah S, Brans B, Hoekstra O, Teule G . The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. Q J Nucl Med Mol Imaging. 2007; 52(1):30-6. View

11.

Treglia G, Bertagna F, Sadeghi R, Verburg F, Ceriani L, Giovanella L . Focal thyroid incidental uptake detected by ¹⁸F-fluorodeoxyglucose positron emission tomography. Meta-analysis on prevalence and malignancy risk. Nuklearmedizin. 2013; 52(4):130-6. DOI: 10.3413/Nukmed-0568-13-03. View

12.

Araz M, Soydal C, Demir O, Gokcan M, Kucuk N . The Role of F-FDOPA PET/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels. Mol Imaging Radionucl Ther. 2023; 32(1):1-7. PMC: 9950688. DOI: 10.4274/mirt.galenos.2022.81904. View

13.

Bertagna F, Biasiotto G, Orlando E, Bosio G, Giubbini R . Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature. Jpn J Radiol. 2010; 28(9):629-36. DOI: 10.1007/s11604-010-0488-z. View

14.

Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F . Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014; 2(5):356-8. DOI: 10.1016/S2213-8587(13)70215-8. View

15.

Dong M, Liu Z, Zhao K, Ruan L, Wang G, Yang S . Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun. 2009; 30(8):639-50. DOI: 10.1097/MNM.0b013e32832dcfa7. View

16.

Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H . Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2005; 91(2):498-505. DOI: 10.1210/jc.2005-1534. View

17.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View

18.

Binse I, Poeppel T, Ruhlmann M, Gomez B, Umutlu L, Bockisch A . Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?. Eur J Nucl Med Mol Imaging. 2015; 43(6):1011-7. DOI: 10.1007/s00259-015-3288-y. View

19.

Wierts R, Brans B, Havekes B, Kemerink G, Halders S, Schaper N . Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT. J Nucl Med. 2016; 57(7):1027-32. DOI: 10.2967/jnumed.115.168799. View

20.

Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar R, Araman A . Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013; 34(11):1084-9. DOI: 10.1097/MNM.0b013e328364eaab. View